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Objective: To perform a systematic review of the literature regarding the epidemiology of the
association between systemic lupus erythematosus (SLE) and atherosclerotic cardiovascular disease
(CVD), including the increased risk for CVD, as well as the risk factors responsible for development of
CVD in patients with SLE.
Methods: We followed the PRISMA guidelines to systematically search the PubMed database from
inception to June 2012. Studies were selected using predeﬁned eligibility criteria, and 2 authors
independently extracted data. The risk of bias was measured for each study using a domain-based
assessment.
Results: We report on 28 studies that met criteria for inclusion in our analysis. We found strong
epidemiologic evidence that SLE patients have an increased relative risk of CVD compared to controls.
There is limited information regarding relative CVD mortality risks among SLE patients. Traditional CVD
risk factors, including age, male sex, hyperlipidemia, smoking, hypertension, and CRP, are associated
with CVD risk among SLE patients. Several SLE-speciﬁc factors, including disease activity and duration,
and possibly speciﬁc manifestations and therapies, further increase risk. Several risk factors, such as
disease activity and glucocorticoid use, are closely associated, making it difﬁcult to disentangle their
effects.
Conclusions: CVD risk among SLE patients compared to the general population is at least doubled. While
older SLE patients appear to have the highest absolute risks of CVD, young women have alarmingly high
relative risks, given the rarity of CVD in the comparison general population. Both traditional and SLE-
speciﬁc risk factors are important, although there are discrepancies within the literature.
& 2013 Elsevier Inc. Open access under CC BY-NC-ND license.Cardiovascular disease (CVD) is a well-recognized complica-
tion of systemic lupus erythematosus (SLE). Urowitz et al. ﬁrst
described a bimodal mortality pattern among SLE patients in
1976, with an early peak in the ﬁrst 3 years after diagnosis due to
active disease, infections and glomerulonephritis, and later
deaths, 4–20 years after SLE diagnosis, due to CVD [1]. Since
then, there has been a growing interest in both the epidemiology
and pathophysiology of CVD among SLE patients. Although overall
mortality for patients with SLE has improved over the pastfting; CAD, coronary artery
ve protein; CV, cardiovascu-
lar accident; MI, myocardial
stemic lupus erythematosus
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Costenbader).
C-ND license.30 years with advances in treatment and better understanding
of disease mechanisms, mortality due to CVD has remained the
same [2]. The biology and mechanisms underlying accelerated
atherosclerosis in SLE are complex and remain areas of active
investigation. Although traditional risk factors such as hyperlipi-
demia and smoking have been shown to predict cardiovascular
disease in patients with SLE, SLE itself is an independent risk
factor for CVD, and a number of SLE-speciﬁc risk factors for CVD
have been studied [3].
Several types of ‘cardiovascular disease’ are observed among
individuals with SLE, including pericarditis, myocarditis, conduc-
tion system disease, vasculitis and valvular disease. In this review,
we concentrate upon atherosclerotic CVD including coronary
artery disease (CAD), cerebrovascular disease (cerebrovascular
accidents, CVAs; and transient ischemic attacks, TIAs), congestive
heart failure (CHF) and peripheral vascular disease (PVD). We also
review the body of evidence on both traditional and disease-
speciﬁc risk factors, highlighting some discrepancies within the
literature.
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Search strategy and selection criteria
We used the PRISMA guidelines for conducting a systematic rev-
iew as a basis for our search protocol [4]. We searched the PubMed
database from inception to June 2012, restricted to the English
language with the following search terms: ‘‘lupus AND’’; ‘‘angina’’;
‘‘atherosclerosis’’; ‘‘cardiovascular’’; ‘‘cardiovascular mortality’’; ‘‘cer-
ebrovascular accident’’; ‘‘congestive heart failure’’; ‘‘coronary artery
disease’’; ‘‘coronary heart disease’’; ‘‘myocardial infarction’’; ‘‘periph-
eral vascular disease’’; and ‘‘stroke.’’ We excluded review articles,
nonhuman studies, case reports, basic science studies pertaining
to the mechanism of atherosclerotic disease, and studies related to
non-atherosclerotic cardiovascular disease such as pericarditis, myo-
carditis, conduction system disease, vasculitis and valvular disease.
We also excluded articles that focused only on the antiphospholipid
antibody syndrome without concomitant SLE. We limited our search
to studies that examined clinical endpoints such as CAD, CHF, CVA,
PVD or CVD mortality and excluded studies that had subclinical
atherosclerosis as an endpoint. We also conducted hand searches of
reference lists to ensure that we did not miss any articles.
We aimed to address the following questions: [1] what is the
risk of cardiovascular disease, speciﬁcally CAD, CHF, CVA, PVD
and CVD related mortality among SLE patients compared to the
general population? and [2] what are the risk factors for the
development of CVD among SLE patients?
Data extraction
SS screened all abstracts and applied the eligibility criteria in
order to identify studies that were appropriate for inclusion. SS and
SK then independently extracted data using predeﬁned criteria,
which included date of publication, population, language, study3682 articles identified through
database search
3684 articles screened
546 abstracts screened
28 articles included in final
analysis (7for CVD section,
1 for CVD mortality section,
20 for Risk Factor section)
Fig. 1. Flow diagram of litdesign, duration, participant data, outcome deﬁnition, results,
funding and risk of bias (Appendix Table A1–A4). Risk of bias was
broken down into 3 domains including selection bias, measurement
bias and confounders, as adapted from Cochrane Database guide-
lines (Appendix Tables A2 and A4) [5]. Any disagreements were
reconciled by consensus and by KC. This data extraction process was
done for the studies involving the risk of CVD in SLE patients as well
as for the papers that looked at risk factors for CVD in SLE patients.Results
Through our screening process, we identiﬁed 28 studies that
met the criteria for inclusion in our analysis. Seven of these
studies pertained to the risk of symptomatic atherosclerotic
disease in SLE patients compared to the general population;
1 study examined the risk of CV related death among SLE
patients; and 20 studies related to the risk factors for sympto-
matic atherosclerotic disease among SLE patients (Fig. 1).Risk of symptomatic atherosclerotic disease in SLE patients
compared to the general population
Coronary artery disease (CAD)
The increased risk of myocardial infarction (MI) and angina
among SLE patients has been well characterized in a number of
population-based studies. The 6 papers examined in this review
include 4 cohort and 2 case-control studies comprising 15,822 SLE
patients with 1232 events related to CAD (Appendix Table A1)
[6–11]. Most studies reported a 2–10 fold increase in the risk of
MI among SLE patients, with a greater increase in relative risk
generally observed in younger patient groups (Fig. 2). The most
striking of these studies was conducted by Manzi et al. who2 articles identified through other
sources
3138 excluded (review, basic
science, case reports, not
atherosclerotic disease)
518 excluded (not atherosclerotic
disease, subclinical endpoints)
erature search strategy.
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Fig. 2. Forest plots of study effect estimates and population sizes for epidemiologic studies investigating the risk of MI among SLE patients compared to the general
population by age group. (a) Studies with all age groups combined. (b) Studies stratiﬁed by age group for older SLE patients. (c) Studies stratiﬁed by age group for younger
SLE patients. *The size of the diamond reﬂects the size of the study population. *The position of the diamond reﬂects the risk estimate and the length of the bars reﬂects the
95% conﬁdence interval. *OR ¼ odds ratio, CHD ¼ coronary heart disease (MI, CABG, and angioplasty), RR ¼ relative risk, SIR ¼ standardized incidence ratio, NS ¼ not
speciﬁed how many patients in each subgroup, PMR ¼ proportionate morbidity ratio.
S.R. Schoenfeld et al. / Seminars in Arthritis and Rheumatism 43 (2013) 77–95 79compared 498 SLE patients in the University of Pittsburgh cohort
to age-matched controls from the Framingham Heart Study in a
retrospective cohort analysis [7]. They found that young women
aged 35–44 with SLE had a staggering 52.4 (95% CI 21.6–98.5)
times increased relative risk of MI over an average of 6.7 years of
observation compared to their aged-matched controls, a group
with a very low absolute risk of MI. Older women with SLE also
had an elevated relative risk of MI, although this risk was only
2–5 fold higher than controls. The strength of this study was the
relatively large number of SLE patients examined, while limita-
tions included that CV events were initially identiﬁed by self-
reporting and many confounders were not controlled for in the
statistical analysis (Appendix Table A2).
Studies in other populations have also found that the greatest
increase in relative risk for MI is among younger patients,
suggesting that SLE patients have premature and accelerated
atherosclerosis and cardiac events compared to their healthy
peers. In a retrospective analysis of patients admitted to California
hospitals between 1991 and 1994, Ward used billing codes to
demonstrate that SLE patients were approximately twice as likelyto be admitted to the hospital for acute MI compared to age-
matched controls, again with the most important increase in
relative risk among those patients under 44 years of age [8].
In patients older than 45, there was no difference in the rate of
hospitalization for acute MI between those with and without SLE.
Ward’s ﬁndings are particularly signiﬁcant as he examined the
data of over 8000 SLE patients, but are biased by the fact that he
looked exclusively at patients who were hospitalized, thus focus-
ing on a more ill subset of the population.
More recently, a population-based study from Sweden by
Bengtsson et al. identiﬁed SLE patients from rheumatology,
internal medicine and dermatology practices as well as all 140
national healthcare centers and 1 private practitioner ofﬁce in
4 counties in Northern Sweden and compared them to the general
population in the same region, speciﬁcally evaluating incidence
rates of MI and stroke in a 7-year follow-up period [11]. SLE
patients had a greater than 2-fold increased risk of MI when
compared to the general population over the 7-year follow-up
period. Again, the most strikingly elevated relative risk was seen
among likely premenopausal female patients, aged 40–49, among
S.R. Schoenfeld et al. / Seminars in Arthritis and Rheumatism 43 (2013) 77–9580whom there was an 8.7-fold increased risk of MI during the same
follow-up period. This study, like that of Ward, looked only at
events that required hospitalization and may have missed sub-
acute CV events, but was unique in looking at all SLE patients
within a deﬁned geographic region.
Three large population-based studies, 1 in Sweden, 1 in the UK
and 1 in the US, found an overall 2- to 3-fold increase in CVD
events in SLE patients compared to the general population
[6,9,10]. In a 2012 nationwide retrospective study by Zoller
et al., all individuals in Sweden hospitalized with a main diagnosis
of autoimmune disease without previous or coexisting CVD were
followed for ﬁrst hospitalization for MI or angina [6]. In over 6000
patients hospitalized for SLE between 1964 and 2008, the like-
lihood of hospitalization for new CVD in the ﬁrst year after
discharge was nearly 5 times that of patients without SLE who
were matched for age, socioeconomic status, and multiple
medical comorbidities. This relative risk dropped to about 1.6 after
10 years had elapsed from initial hospitalization. As this study
only looked at hospitalized patients it may overestimate CVD
incidence.
A 2004 study by Fischer et al. employed data from the United
Kingdom General Practice Research Database in a case-control
analysis [9]. They found that SLE patients, identiﬁed through
billing codes, had 2.67-times overall relative risk of developing an
acute MI compared to patients without SLE. This study included a
slightly older group of patients, as greater than 90% of the study
population was older than 50 years of age and 50% were 70–89
years of age. In addition, the study was limited by its size,
examining only 15 patients with SLE with an inadequate number
of controls. In a large prospective population-based study using
the Nurses’ Health Study, Hak et al. compared rates of CV events
among incident SLE patients to rates among participants who
were not diagnosed with SLE [10]. They demonstrated a 2- to
3-fold increase in cardiovascular events in the women with SLE
compared to the rest of the cohort during the 28-year study
period. After adjusting for a number of potential confounding
factors including age, hypertension, diabetes, hypercholesterole-
mia, parental history of CAD before age 60, BMI, physical exercise,
smoking status, alcohol consumption, menopause status, use of
hormone replacement therapy, race, use of aspirin, NSAIDS and
glucocorticoids, they found that the relative risk for any coronary
heart disease was slightly greater than 2, with a higher relative
risk for coronary artery bypass grafting (CABG) or angioplasty
than for MI. The average age of the study participants was 56,
again slightly older than in other SLE studies, and the patient
population was not necessarily representative of the general SLE
population as all participants in the cohort were female nurses
and predominantly white (95% of the cohort).
In the 3 studies that performed age-stratiﬁed analyses, several
of the CAD-risk estimates were not statistically elevated for older
SLE populations [7,8,11] (Fig. 2). The heterogeneity among these
studies may stem from the different epidemiologic methods
employed. For example Ward’s study estimated proportionate
morbidity ratios for hospitalized patients, while the study by
Manzi et al. compared SLE patients followed in an academic
cohort study to healthy individuals followed in another
community-based cohort study. Additionally, the small sizes of
some of the subgroups were likely underpowered to detect risk
elevations. The lack of a reproducible risk estimate for CAD in
older SLE populations likely also reﬂects a lower relative risk, due
to the increased prevalence of CAD in the general population.
Congestive heart failure (CHF)
Epidemiologic data also suggest that SLE patients have an
increased risk of CHF compared to the general population. Ourreview found only 1 study that compared the risk of CHF among
SLE patients to healthy controls [8]. Using the California Hospital
Discharge Database, Ward reported that SLE patients were 1-to
3-times more likely to be admitted to the hospital with CHF
compared to age- and sex-matched non-SLE counterparts [8]. SLE
patients aged 18–44 were 2.61 times more likely to be hospita-
lized for CHF, whereas 45–64 year old patients had no statistically
signiﬁcant increase in CHF admissions and the oldest age group,
over 65 years old, was only 1.26 more likely to be admitted for
CHF. Given the low absolute risk of CHF among young healthy
individuals, this study highlights the increase in relative risk of
CHF in young SLE patients. The underlying cause of CHF (i.e. due
to ischemia, hypertension, or valvular heart disease) could not be
obtained from this administrative database. However, data from
a separate large multicenter cohort of 1249 patients followed over
8 years demonstrated that only 21% (5/24) of the cases of CHF
were attributable to atherosclerosis, suggesting that CHF among
SLE patients is likely multifactorial in etiology [12].
Cerebrovascular disease
SLE patients have an increased risk of stroke when compared
to control populations, similar to that seen for MI and CHF. Our
review examined four studies comprising 9657 SLE patients and
177 cerebrovascular events (Fig. 3) [8,10,11,13]. Ward found that
in the 18–44 year old age group of SLE patients, the risk of stroke
was 1.75 times that of age-matched controls [8]. The increased
relative risk diminished with age such that SLE patients over age
65 actually had a somewhat lower overall risk of stroke than
controls. Hak et al. reported a 2.29-fold increased risk of stroke
among older incident SLE patients compared to other population-
based women in the Nurses’ Health Study Cohort [10]. Mok et al.
similarly found a 2-fold increase in the risk of CVAs among all SLE
patients over an 8-year period at a single institution in Hong
Kong; this risk was 22-fold higher for the youngest group of SLE
patients [13]. Bengtsson et al. further corroborated these results
in their population-based Swedish study where they demon-
strated that the risk of stroke and/or MI in the total SLE popula-
tion was 1.27 fold higher than the general population, but among
women with SLE aged 40–49 it was 8-fold higher over the 7-year
follow-up period [11].
As with the risk estimates of CAD, CVA risk estimates were
most strikingly increased for younger SLE patients, but less
consistently elevated among older SLE patients (Fig. 3). Again,
the small sizes of the subgroups and the different study designs
may account for some of the variation in ﬁndings [8,11,13].
A major limitation to most of these studies, and certainly to all
of the administrative database studies, is the lack of data
concerning SLE-related comorbidities, such as hypertension, anti-
phospholipid syndrome, renal failure, and valvular heart disease
in particular.
Peripheral vascular disease (PVD)
Our review found no data regarding the relative risk of PVD
among SLE patients compared to population-based controls. Sev-
eral research groups have reported prevalence rates in SLE cohorts.
In the Systemic Lupus International Collaborating Clinics-Registry
for Atherosclerosis (SLICC-RAS) cohort, there were 8 cases of PVD
among 1249 patients during a 2-year period [12]. In the Lupus in
Minorities: Nature vs. Nurture study (LUMINA), a large multi-
center, multiethnic inception cohort, 5.3% of 637 patients devel-
oped PVD over a mean follow-up of 4.4 years [14]. The average age
of this population was young (36.5 years) and, strikingly, a
signiﬁcantly greater percentage of patients with PVD died during
this time compared with patients who did not have PVD (32% vs.
0.1 1 10 100
0.1 1 10 100
0.1 1 10 100
Fig. 3. Forest plots of study effect estimates and population sizes for epidemiologic studies investigating the risk of CVA among SLE patients compared to the general
population by age aroup. (a) Studies with all age groups combined. (b) Studies stratiﬁed by age group for older SLE patients. (c) Studies stratiﬁed by age group for younger
SLE patients. *The size of the diamond reﬂects the size of the study population. *The position of the diamond reﬂects the risk estimate and the length of the bars reﬂects the
95% conﬁdence interval. *CVA ¼ cerebrovascular accident, SIR ¼ standardized incidence ratio, RR ¼ relative risk, MI ¼ myocardial infarction PMR ¼ proportionate
morbidity ratio, NS ¼ not speciﬁed how many patients in each subgroup.
S.R. Schoenfeld et al. / Seminars in Arthritis and Rheumatism 43 (2013) 77–95 8114%, p ¼ 0.0043). PVD likely predicts either more severe SLE
activity or more widespread atherosclerotic disease.Risk of CVD mortality in SLE patients
Although there have been multiple studies addressing the
increased risk of CVD in SLE patients, the risk of death from
CVD among SLE patients compared to controls has not been well
described. In the 1 study to address this question, Bjornadal et al.
used the Hospital Discharge Register and Cause of Death Register
in Sweden [2]. They included 4737 patients with a diagnostic code
for SLE discharged from the hospital for the ﬁrst time between
1964 and 1994 and compared the causes of death to those of the
general Swedish population. Although the authors estimated that
their study encompassed approximately 80% of the SLE patients in
Sweden, their results likely overestimated the increased risk of
death from CVD among patients with SLE, given that theyincluded only hospitalized and more severely ill SLE patients.
The overall standardized mortality ratio (SMR) for SLE patients
compared to the general Swedish population was 3.63. When
cause of death was examined, the SMR for any CVD cause of death
was 2.97, while for CAD alone it was 3.03. Younger patients were
again at higher relative risk for CVD death compared to age-
matched controls; patients aged 20–39 at the time of discharge
had a 16-fold increased risk of dying from a CVD event compared
to controls. As this study spanned 30 years, it was able to track
overall and speciﬁc causes of death. There was a reduction in all-
cause mortality, in particular from infections and renal failure,
among SLE patients over time but there were no changes in death
rates due to CVD. It could be that, in recent years, as fewer SLE
patients succumb to the early complications of disease, they are
now living to experience CVD outcomes, despite increasing
recognition and better treatment of CVD risk factors.
In summary, we have found strong epidemiologic evidence of
at least 2- to 3-fold elevated risks of MI, CHF, cerebrovascular
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S.R. Schoenfeld et al. / Seminars in Arthritis and Rheumatism 43 (2013) 77–9582disease and overall CVD mortality among patients with SLE
compared to the general population. There are no epidemiologic
studies of PVD risk among patients with SLE. The preponderance
of the epidemiologic data point to particularly elevated relative
risks of CVD among young patients who have low background
CVD risk. However, the risks are also elevated among older SLE
patients.H
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Considerable research has focused on identiﬁcation of SLE
patients who are at highest risk for CVD, and speciﬁcally on the
identiﬁcation of potentially modiﬁable risk factors. Both tradi-
tional and SLE-related risk factors have been examined
(Tables 1 and 2). Through our review process, we identiﬁed 20
studies that met criteria for inclusion in our analysis for this
section. These included 17 cohort studies and 3 case-control
analyses, comprising 10,426 SLE patients (Appendix Table A3).T
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Hyperlipidemia
The inﬂammatory milieu of SLE leads to dysregulation of lipid
metabolism pathways, which contributes to the increased risk of
atherosclerotic disease among SLE patients [15,16]. Five large
cohort studies have shown hypercholesterolemia to be a signiﬁ-
cant risk factor for CVD in SLE patients [7,17–20]. On average,
total cholesterol was associated with a 1- to 2-fold increased risk
of CVD events in these studies. Goldberg et al. and Touma et al.
also found that elevated triglycerides were predictive of CAD,
deﬁned as MI or angina [17,21]. Although Touma et al. had a large
cohort and was therefore one of the bigger studies, their outcome
deﬁnition and measurement methods were not clearly deﬁned,
making it possible that there would be high risk of bias in these
categories (Appendix Table A4). Manzi et al. had a well-
established and clearly deﬁned cohort, but they only controlled
for age in their multivariable analysis, putting their study at
higher risk for potential confounding.
Smoking
Three large cohort studies and 2 smaller Swedish studies have
found that smoking acts as an independent risk factor for CVD in
SLE patients [22–26]. As part of the LUMINA study, Toloza et al.
prospectively followed SLE patients over a median follow-up of
73.8 months and compared those who had a CVD event to those
who did not [25]. All patients had been diagnosed with SLE within
5 years of the start of the study and approximately 7% of patients
had a CVD event (deﬁned as MI, angina, vascular procedure for
ischemic heart disease, stroke or PVD) within the study period.
Current cigarette use was signiﬁcantly associated with a
3.7-times increased risk of having a CVD event. This was a
well-designed study made up of a relatively large cohort that
controlled for a number of variables in the multivariable analysis,
putting their ﬁndings at a relatively low risk of bias (Appendix
Table A4). Urowitz et al. also found that smoking was associated
with a greater than 3-times increased risk of CVD events over an
approximately 8-year period in their study of 561 SLE patients
from the Toronto inception cohort [26]. This study, too, had an
overall low risk of bias by our assessment (Appendix Table A4). In
the PROFILE population, another multicenter, multiethnic study
population, Bertoli et al. found that smoking acted as an inde-
pendent risk factor associated with a 2-fold decrease in time to a
Table 2
SLE-Related Risk Factors Associated with CVD Among SLE Patients.
Author Disease Activity Antiphospholipid Abs Glucocorticoids Hydroxychloroquine Azathioprine Neuropsychiatric Disease
Bengtsson et al. [11] þ þ    N/A
Gustafsson et al. [24]  þ    
Touma et al. [17] þ N/A   þ N/A
Yang et al. [42]    þ N/A 
Nikpour et al. [20] þ  þ þ  
Urowitz et al. [12]  N/A    N/A
Haque et al. [28]     þ 
Gustafsson et al. [23]  þ    
Burgos et al. [14]     þ 
Goldberg et al. [21]  N/A    N/A
Bertoli et al. [22] N/A     þ
Pons-Estel et al. [30]      
Mikdashi et al. [19] þ   N/A N/A N/A
Urowitz et al. [26]      þ
Bessant et al. [29]  N/A   N/A N/A
Ruiz-Irastorza et al. [36] N/A þ  þ  
Toloza et al. [25]  þ    N/A
Manzi et al. [7] N/A N/A  N/A N/A N/A
Petri et al. [34] N/A  N/A N/A N/A N/A
Petri et al. [18] N/A  þ  N/A N/A
Abbreviations: þ ¼ statistically signiﬁcant correlation in multivariate analysis,  ¼ no statistically signiﬁcant correlation in multivariate analysis, N/A ¼ did not examine
variable.
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follow-up period [22]. The outcome deﬁnitions and measurement
methods were not clearly deﬁned in this study, making it difﬁcult
to assess the exact methodology. More recently, in a smaller
study, Gustafsson et al. found that smoking was a risk factor for
CVD mortality (RR 3.4, 95% CI 1.3–9.2) among 208 SLE patients,
a conclusion which was consistent with their earlier ﬁndings that
smoking was predictive of MI, CVA, PVD or CV mortality among
the same patient population [23,24]. Both of these studies had a
relatively low risk of bias by our domain-based bias assessment.
Certainly, smoking cessation should be an important goal for
physicians caring for SLE patients.
Hypertension
In the Toronto Lupus Cohort, 33% of 250 SLE patients were
hypertensive compared to 13% of 250 age-matched controls
(p ¼ 0.001) [27]. In the Hopkins Lupus cohort, the presence of
hypertension or use of antihypertensive medications were inde-
pendent risk factors for CVD (RR not deﬁned) [18]. Two smaller
retrospective case-control studies have also reported that hyper-
tension or treatment for hypertension were associated with a
greater than 2-fold increased risk of CVD [28,29], and 2 recent
studies using data from the Toronto Lupus Cohort found that
hypertension was associated with a 1- to 2-fold risk of CAD
among SLE patients [17,20]. Mikdashi et al. also found that
hypertension predicted a greater than 2-fold risk of stroke in
SLE patients [19]. A potential concern regarding the study by
Haque et al. is that data about participants’ lipid status, family
history and ethnicity was missing in nearly 20% of the cases.
Sex
While most SLE cohorts are comprised predominantly of
women, the risk of CVD events, as in the general population,
appears higher among men. In each of the 2 large cohort studies,
SLICC and LUMINA, male SLE patients had a nearly 4-fold
increased risk of experiencing a CVD event compared to females
[12,30]. Although both studies were comprised of large databases
and were well conducted, it should be noted that nearly 90% of
the patients were females in both studies. Similarly, in apopulation-based study by Nikpour et al., males had a nearly
2-fold increased risk of MI, angina and sudden cardiac death,
although again the cohort was comprised of only 10% males [20].
A strength of the study by Nikpour et al. was that all outcomes
were validated by a cardiologist, making the risk of bias for
outcome measurement relatively low (Appendix Table A4).
Age
Older age is a relatively consistent independent predictor of
CVD events among SLE patients. Gustafsson et al. found the
strongest correlation between age and cardiovascular events,
with age predicting a 2- to 3-fold increase in CVD events and
CVD death [23]. A number of other studies have found a weaker
correlation between age and CVD among SLE patients
[7,12,14,17,20–22,25,30].
C-reactive protein (CRP)
Unlike in the general population, where high sensitivity CRP
has clearly been shown to be associated with increased risk of
CVD [31], this ﬁnding is less consistent among SLE patients. In the
LUMINA study [25,30], as well as in a smaller study involving 208
Swedish SLE patients [24], elevated CRP levels were associated
with anywhere between a 1.5 and 3.3 increased CVD risk.
However, most of the other large SLE cohorts have not examined
CRP in their analyses [7,12,18,26]. Although the 3 studies that
found CRP to be associated with CVD were all well designed and
executed, it is difﬁcult to draw conclusions about the role of CRP
in CVD among SLE patients given the inconsistency in the
literature.
Homocysteine
Elevated homocysteine levels may act as an independent risk
factor for atherosclerotic CVD in the general population [32,33]
and among those with SLE [34]. Petri et al. studied 337 SLE
patients and compared homocysteine levels in those patients who
had a stroke or thrombotic event versus those who did not over a
mean follow-up period of 4.8 years [34]. Twenty-nine patients
had a stroke during the follow-up time and 31 patients had an
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gangrene of the ﬁngers or other arterial thrombosis. After adjust-
ing for age, sex, race, obesity, hypercholesterolemia, hypertension,
diabetes, renal insufﬁciency and presence of the lupus antic-
oagulant, homocysteine remained an independent predictor of
stroke and arterial thrombotic events. One of the strengths of this
study lies in the fact that it controlled for a number of important
variables in the multivariable analysis.
Diabetes mellitus
None of the studies we identiﬁed found that diabetes or
treatment for diabetes was an independent risk factor for CVD
among SLE patients. Many of the cohort studies have not
examined diabetes as a risk factor, again highlighting their
heterogeneity [22,29]. Those studies that did include diabetes
had small numbers of diabetic patients [26,30].
Obesity
Similarly, obesity has not been frequently examined in relation
to CVD risk in SLE populations [7,26,29]. Only 1 study in the early
1990s has reported that obesity was correlated with an increased
risk of CVD events (RR not reported) [18]. In summary, there is
strong epidemiologic evidence that traditional CVD risk factors
also elevate CVD risk among SLE patients.Disease-speciﬁc factors
While traditional CVD risk factors, in particular hypertension,
smoking and hyperlipidemia, are undoubtedly important in
increasing the CVD risk among SLE patients, studies have shown
that these risk factors do not fully account for the elevated risk of
CVD in this patient population [3]. Several CVD risk factors related
to inﬂammation and SLE have been identiﬁed in epidemiologic
studies and are summarized here, although there are inconsis-
tencies in the literature as to which of these are the most
predictive (Table 2).
SLE disease activity
The importance of disease activity in predicting CVD outcomes
has been variable among different studies. For example, the SLICC
cohort found that SLE disease activity, as measured by SLEDAI-2K,
was not an independent predictor of CVD events [12]. It is
important to note, however, that this study involved an inception
cohort of patients who enrolled in the study within 15 months of
diagnosis. Given the early stage of disease of these patients, SLE
disease-related factors or treatments may not have played as
large a role. Other studies have indeed found disease activity to be
an important predictor of CVD events [11,17,19,20]. In a recent
study of 269 SLE patients in Northern Sweden, Bengtsson et al.
found that a higher SLEDAI score predicted both stroke and MI
among SLE patients followed over 7 years [11]. It should be noted
that this study used information from an inpatient database and
would therefore miss events not requiring hospital admission.
Nikpour et al. and Touma et al. similarly found that disease
activity, as measured by SLEDAI-2K was predictive of a modest
increase risk of CAD during a 6- and 37-year follow-up period,
respectively. Mikdashi et al. reported that baseline SLEDAI-2K
scores were associated with a 2-fold increased risk of stroke
within 8 years [17,19,20]. Measures of SLE disease activity,
including the SLEDAI, BILAG and SLAM, used in many of the
studies we reviewed, have been criticized as being insensitive andmay not accurately capture systemic inﬂammation that could
drive atherosclerosis.
SLE disease duration
We identiﬁed only 2 studies that examined duration of SLE as a
risk factor for incident CVD event and they arrived at no clear
consensus. Manzi et al. found that longer disease duration
appeared to be protective for CVD (rate ratio 0.82, 95% CI 0.74–
0.92) among women in the Pittsburgh SLE Cohort [7]. Toloza et al.,
however, reported that increasing duration of SLE was associated
with increased risk of all types of vascular events in the LUMINA
cohort study [25]. Not only is accurately deﬁning SLE disease
duration a challenge, but several variables, including age itself, as
well as SLE-related damage and total cumulative-steroid dose, all
parallel increases in SLE disease duration.
Neuropsychiatric disease
Although likely a proxy for more severe disease and potentially
for increased glucocorticoid use, a number of studies have
demonstrated a correlation between neuropsychiatric SLE and
an increased risk of cardiovascular events. In particular, Urowitz
et al. found that neuropsychiatric disease predicted a nearly
4-fold increased risk of cardiovascular events including MI,
angina, TIA, stroke, PVD and sudden death [26]. In another large
study, Bertoli et al. found that both psychosis and seizure were
independent predictors of time to a CVD event, although again it
should be noted that it was not clear how these outcomes were
assessed in this study [22].
Antiphospholipid antibodies
The antiphospholipid antibody syndrome is characterized by
an increased risk of stroke and MI [35], and many studies have
therefore tried to determine whether the presence of antipho-
spholipid antibodies may be an independent risk factor for CVD
among SLE patients. In the LUMINA study, the presence of a
positive antiphospholipid antibody was signiﬁcantly associated
with 4-times increased risk of having a CVD event over a median
of approximately 6 years [25]. The presence of antiphospholipid
antibodies was also associated with a greater than 4-fold
increased risk of ﬁrst time MI, stroke or PVD in a study of 182
SLE women followed for a mean of 8.3 years, and a later study by
the same group again demonstrated that a positive antipho-
spholipid antibody titer predicted a greater than 2-fold increased
risk of CVD related mortality [23,24]. Bengtsson et al. found that
anticardiolipin IgG predicted a 3-fold increased risk of stroke, but
not MI, in their study of 269 SLE patients [11]. Finally, in a Spanish
study by Ruiz-Irastorza et al. the presence of a positive antipho-
spholipid Ab was associated with a nearly 3-fold risk of throm-
bosis or death, but it should be noted that DVT and PE were
included in this analysis as well as atherosclerotic vascular events
[36]. In addition, this study controlled for relatively few factors in
their multivariable analysis, placing their ﬁndings at a higher risk
of bias.
Glucocorticoids
In general, the examination of medications and risk of CVD is
problematic in that there may be much confounding by indica-
tion. More severely ill SLE patients are more likely to receive
glucocorticoids and other immunosuppressants, while those with
milder disease may be more likely to receive hydroxychloroquine
alone. The relationship between glucocorticoid use and CVD risk
among SLE patients is difﬁcult to fully elucidate as increasing
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activity [37]. While glucocorticoids decrease systemic inﬂamma-
tion, thereby having the potential to decrease atherogenesis, their
use correlates with exacerbation of multiple traditional risk
factors, including total cholesterol, blood glucose, body mass
index and systolic blood pressure [37]. Petri et al. demonstrated
that longer duration of glucocorticoid use was independently
associated with incident CVD events although the relative risk
was not quantiﬁed in that study [18]. Nikpour et al. also found
that glucocorticoid use independently predicted a 2-fold increase
in the risk of MI, angina and sudden cardiac death (RR 2.01, 95% CI
1.19–3.41) [20], but other studies have not replicated these
ﬁndings [7,12,25,26,29,30]. Part of the discrepancy among studies
may stem from the different ways in which glucocorticoid use has
been quantiﬁed, including duration of use and maximum, current
or total dose [11,12,18,20,23,26,30], and the difﬁculty of separat-
ing disease activity from glucocorticoid use.
Hydroxychloroquine
It has been clearly demonstrated that hydroxychloroquine has
a favorable effect on lipid proﬁles and glycemic control among
SLE patients [38–40]. Whether hydroxychloroquine has an effect
on CVD outcomes is less clear, although it has been associated
with increased survival among patients with SLE [41]. Nikpour
et al. and Ruiz-Irastorza et al. both found that hydroxycholor-
oquine use conferred a 50–60% decrease in risk of CVD events
[20,36]. Similarly, a small retrospective case-control study in
China found that hydroxychloroquine use was protective against
the development of CVD, although there were only 28 SLE
patients in this analysis and the authors controlled for few
variables in their multivariable analysis [42].
Azathioprine
Finally, 2 studies have reported that azathioprine use is an
independent risk factor for CVD among SLE patients, predicting a
3-fold increased risk of PVD in 1 study [14] and of MI and angina
in another [28]. In a study by Touma et al., immunosuppressive
medications including azathioprine were associated with an
increased risk of CAD [17]. Most studies have not examined
azathioprine as an independent predictor; and azathioprine, like
glucocorticoid use, is correlated with more severe SLE. In sum-
mary, SLE-related factors that have been demonstrated to be
associated with increased CVD risk include physician’s assessment
of SLE activity, neuropsychiatric lupus, antiphospholipid antibo-
dies, and potentially glucocorticoid and azathioprine therapy
[11,14,17–20,22–26,28,36,42]. The discrepancies between studies
as to the relative importance of the factors may be due to different
methodologies and study designs. In addition, most of these
factors are highly correlated. Increasing age and longer duration
of SLE are strongly associated, for example, as are SLE disease
activity measures and use of glucocorticoids and immunosuppres-
sants [37]. Despite the variability in study design and covariates, it
is clear that while young patients have the most profound increase
in CVD risk, relative to the low absolute risk for their age group,
both SLE disease activity and glucocorticoid use increase the
absolute risk of CVD for an SLE patient.
A number of other traditional and disease-speciﬁc risk factors
have been shown in single studies to be predictors of CVD among
SLE patients. These include number of years of education, family
history of CVD, warfarin use, cystatin C level, absence of throm-
bocytopenia, proteinuria, anti-Smith Ab, soluble VCAM level,
B2GP1 and the CPR2C allele [14,22–24,30,42]. While many of
these variables may represent true risk factors, we do not feel thatthese can be classiﬁed as deﬁnitive risk factors at this time given
the paucity of reproducible data.Discussion
The epidemiologic data strongly support that SLE patients are at
elevated relative risk of CVD. The risks of MI, CHF, CVA and CVD
mortality are all increased among SLE patients compared to general
population risks. Younger patients with SLE have the greatest relative
risk compared to their healthy counterparts, but the absolute risk of
CVD among SLE patients increases with advancing age.
From the epidemiologic studies to date, it appears that
traditional CVD risk factors, including hyperlipidemia, cigarette
smoking, advancing age, hypertension, male sex, and elevated
C-reactive protein are all associated with increased CVD risk among
SLE patients. However, past studies have not simultaneously exam-
ined all of these risk factors in the same populations, so comparisons
of the relative risk associated with each are not possible. In addition
to traditional CVD risk factors, several SLE-associated factors have
also been predictive of CVD risk in past cohort studies. These include
increased SLE disease activity, potentially neuropsychiatric SLE
manifestations in particular, and use of azathioprine and glucocorti-
coids (which are inextricably linked to disease severity). Antipho-
spholipid antibodies in SLE patients are clearly related to increased
risk of CVAs, but less clearly to increased risk of atherosclerotic CVD.
The variability regarding the relative importance of risk factors for
CVD among SLE patients in past epidemiologic studies is likely due
in part to different design methods and different patient and
comparison groups. In addition, there are inconsistencies with
regard to which factors are considered simultaneously in multi-
variable models, and it is difﬁcult to separate inherently related
factors. Unfortunately, many SLE-related factors, such as disease
activity, organ damage and antiphospholipid antibodies are not
included in administrative data.
It has been proposed that SLE should be treated as a ‘‘CVD
equivalent’’ such as diabetes mellitus is, with lower lipid goals,
more aggressive aspirin use and potentially more aggressive
monitoring [43]. For the physician caring for a patient with SLE,
the implications of the studies reviewed here include that
aggressive screening and management of traditional CVD risk
factors should be the goal. All modiﬁable risk factors, in particular
hyperlipidemia, hypertension and smoking, should be addressed
in an effort to reduce CVD risk. It has not yet been proven,
however, that this effort will reduce CVD risk to the same extent
as in the general population. Recent studies have started to
address whether traditional treatment regimens may prevent or
slow atherosclerosis in SLE patients. The recent randomized
controlled Lupus Atherosclerosis Prevention Study by Petri et al.
suggests that atorvastatin did not in fact slow progression of
subclinical atherosclerosis in 200 SLE patients over 2 years [44]. A
similar trial in a pediatric SLE population also did not show any
effect of atorvastatin on the progression of carotid IMT [45].
Another implication for treating physicians is that SLE disease
activity contributes to CVD risk and treating it to reduce disease-
related inﬂammation should also be an objective. There is an
expanding ﬁeld of literature suggesting that antiinﬂammatory
and SLE-speciﬁc agents may modulate CVD risk factors in rheu-
matic diseases. A recent study examining whether mycopheno-
late mofetil use was correlated with a reduction in subclinical
atherosclerotic progression did not show an effect, although this
was a small study with a relatively short period of follow-up [46].
As further biomarkers and molecular pathways of atherogenesis
among SLE patients are identiﬁed, the hope is that we will be able
to better stratify patients to prevent and treat complications of
atherosclerosis in this population.
Table A1
Data Extraction Sheet for Studies Investigating Risk of CVD Among SLE Patients Compared to the General Population.
Author Date
Published
Population Language Study Design Duration Gender Age Race Country Outcome
Deﬁnition
Results Funding
Source
Bengtsson
et al. [11]
2012 277 SLE cases,
Northern
Sweden; 554
controls,
Northern
Sweden
English Prospective cohort 7 years 84.5% F 51.2 (mean) Not speciﬁed Sweden SIR for CVE (MI and
MI/stroke); time
to event
CVE ¼ 1.27 (95% CI
0.82–1.87); CVE
for F aged 40–49
¼ 8.00 (95% CI
1.65–23.38); MI
¼ 2.31 (95% CI
1.34–3.7); MI for
F ¼ 1.75 (95% CI
0.84–3.22); MI
for M 2.9 (05% CI
1.16–5.98); MI
for F aged 40–49
¼ 8.7 (95% CI
1.1–31.4).
County council
for Northern
Sweden, Umea,
Sweden and
Research
Development
Department,
Jamtland
County
Council,
Sweden
Zoller et al.
[6]
2012 6142 SLE cases
hospitalized
for SLE w/o
h/o CHD,
Sweden;
controls total
population of
Sweden
English Retrospective
cohort
45 years 60.3% F (IMD);
42.7% F
(controls)
50 to 470, age
stratiﬁed
Not speciﬁed Sweden SIR for CHD (MI,
angina)
1 year f/u ¼ 4.94
(95% CI 4.15–
5.83); for all
years f/u ¼ 2.27
(95% CI 2.14–
2.42)
Swedish
Research
Council,
Swedish
Council for
Working Life
and Social
Research,
Formas, and
Region Skane
Hak et al.
[10]
2009 148 SLE cases,
Nurses
Health
Study;
119,184
controls,
Nurses
Health Study
English Prospective cohort 28 years 100% F 56 (mean) SLE: 95% White, 4%
Black; Non-SLE:
97% White, 2%
Black
USA RR for total CVD,
CHD (MI, CABG,
angioplasty),
CVA
CVD ¼ 2.26 (95% CI
1.45–3.52); CHD
¼ 2.25 (95% CI
1.37–3.69); CVA
¼ 2.29 (95% CI
0.85–6.15)
NIMH, NIAID,
NICHHD, NIH
Mok et al.
[13]
2009 490 SLE cases,
rheumatol-
ogy and
lupus clinic
Tuen Mun
Hospital,
Hong Kong;
controls
hospitalized
for CVA at
same
hospital
English Retrospective
cohort
8 years 92% F 46.4 (mean) Not speciﬁed Hong Kong SIR for CVA Total ¼ 2.02 (95%
CI 1.3–3.81); age
o30 ¼ 22.8
(95% CI 5.67–
91.7); age 30–39
¼ 21 (95% CI
7.84–56.5); age
40–49 ¼ 7.44
(95% CI 3.33–
16.6); age 50–59
¼ 1.88 (95% CI
0.6–5.84); age
60–69 ¼ 2.8
(1.03–7.6); age
470 ¼ 0.53
(95% CI 0.07–
3.81)
Not speciﬁed
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Fischer et al.
[9]
2004 15 SLE cases
with ﬁrst
time AMI,
GPRD UK; 26
controls
same
database
English Case control 7 years 46.6% F (SLE);
73% F
(controls)
r89 Not speciﬁed UK OR of 1st time MI MI ¼ 2.67 (95% CI
1.34–5.34)
Study not
directly funded
(support from
Swiss NSF, EU
grant,
Bundesamt fur
Bildung und
Wissenschaft)
Ward [8] 1999 8742 SLE cases
hospitalized
for CVD,
California
Hospital
Discharge
Database;
43,710
controls,
same
database
English Case control 4 years 100% F 18 to 465, age
stratiﬁed
SLE: 56% White,
18% Black, 17%
Hispanic;
Controls: 65%
White, 12% Black,
16% Hispanic
USA PMR for MI, CHF,
and CVA as
reason for
hospitalization
For MI: age 18–44
¼ 1.83 (95% CI
1.03–3.26), age
45–64 ¼ 1.02
(95% CI 0.77–
1.34), age 465
¼ 0.71 (95% CI
0.54–0.94); for
CHF: age 18–44
¼ 2.61 (95% CI
1.74–3.92), age
45–64 ¼ 1.24
(0.95–1.61), age
465 ¼ 1.26
(1.03–1.54); for
CVA: age 18–44
¼ 1.75 (95% CI
1.11–2.74), age
45–64 ¼ 0.89
(0.63–1.24), age
465 ¼ 0.74
(0.56–0.98)
Unknown
Manzi et al.
[7]
1997 498 SLE cases,
UPMC; 2208
controls,
Framingham
Offspring
Study
English Retrospective
cohort
14 years 100% F 15–74, age
stratiﬁed
SLE: 76%
Caucasian, 22%
African
American, 2%
American Indian,
Asian American,
and Eastern
Indian: Control:
100% Caucausian
USA Rate ratio for CVE
(MI or angina
pectoris)
For MI: age 35–44
¼ 52.43 (95% CI
21.6–98.5), age
45–54 ¼ 2.47
(95% CI 0.9–3.6),
age 55–64 ¼
4.21 (95% CI 0.6–
4.6); for angina:
age 35–44 ¼
2.35 (95% CI 0.4–
11.1)
Commonwealth
of
Pennsylvania
(Department of
Health); Lupus
Foundation of
America,
Western
Pennsylvania
Chapter; and
Pennsylvania
Lupus
Foundation,
Inc.
Abbreviations: SIR ¼ standardized incidence ratio, CVE ¼ cardiovascular event, MI ¼ myocardial infarction, CI ¼ conﬁdence interval, CHD ¼ coronary heart disease, CVD ¼ cardiovascular disease, RR ¼ relative risk, CABG ¼
coronary artery bypass grafting, CVA ¼ cerebrovascular accident, OR ¼ odds ratio, PMR ¼ proportionate morbidity ratio.
S.R
.
Sch
o
en
feld
et
a
l.
/
Sem
in
a
rs
in
A
rth
ritis
a
n
d
R
h
eu
m
a
tism
4
3
(2
0
1
3
)
7
7
–
9
5
8
7
Table A2
Risk of Bias for Studies Investigating Risk of CVD Among SLE Patients Compared to the General Population.
Author Population Study Design Selection Bias Measurement Bias Control for
Confounders
Comments
Representa-
tive of
Population
Participation
Rate
Recall Bias Outcome
Deﬁnition
Outcome
Measure-
ment
Method
Bengtsson et al. [11] 277 SLE cases, Northern Sweden;
554 controls, Northern Sweden
Prospective cohort L L N/A L L L Database for inpatient admissions
and death; would miss events not
requiring hospitalization
Zoller et al. [6] 6142 SLE cases hospitalized for SLE
w/o h/o CHD, Sweden; controls
total population of Sweden
Retrospective cohort H L N/A L L L Only hospitalized patients with SLE,
so likely studying a sicker
population
Hak et al. [10] 148 SLE cases, Nurses Health Study;
119,184 controls, Nurses Health
Study
Prospective cohort H L H L L L All women cohort, all nurses, slightly
higher SES; for CABG and
angiography relied on participant
recall of event
Mok et al. [13] 490 SLE cases, rheumatology and
lupus clinic Tuen Mun Hospital,
Hong Kong; controls hospitalized
for CVA at same hospital
Retrospective cohort L L L L L H Control group was only patients
hospitalized for CVA; do not
describe baseline characteristics of
control group or which variables
they control for
Fischer et al. [9] 15 SLE cases with ﬁrst time AMI,
GPRD UK; 26 controls same
database
Case control H L N/A L L L Small number of patients with SLE;
over 50% male without adequate
number of controls
Ward [8] 8742 SLE cases hospitalized for CVD,
California Hospital Discharge
Database; 43,710 controls, same
database
Case control H L N/A L L L All women and only hospitalized
patients
Manzi et al. [7] 498 SLE cases, UPMC; 2208 controls,
Framingham Offspring Study
Retrospective cohort L L H L L H Relied on self-reporting and reviewed
charts only of self-reported events
Abbreviations: H ¼ high risk that methodology may have resulted in bias in the speciﬁed domain, L ¼ low risk that methodology may have resulted in bias in the speciﬁed domain, N/A ¼ not applicable.
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Table A3
Data Extraction Sheet for Studies Investigating Risk Factors for CVD Among SLE Patients.
Author Date of
Publication
Population Language Study Design Duration Gender Age Race Country Outcome
Deﬁnition
Results Funding Source
Bengtsson
et al. [11]
2012 277 SLE cases,
Northern
Sweden
English Prospective
cohort
7 years 85% F 51.2 (mean) Not speciﬁed Sweden Time to CVE (MI,
stroke)
aCL IgG Ab 3.08 (95% CI
1.32–7.17); high
SLEDAI 1.16 (1.06–
1.26)
County council for
Northern Sweden,
Umea, Sweden and
Research
Development
Department,
Jamtland County
Council, Sweden
Gustafsson
et al. [24]
2012 208 SLE cases,
Karolinska
University
Hospital
English Prospective
cohort
12 years 89% F 47 (mean) 94% Caucasian Sweden Overall mortality,
nonvascular
mortality,CVD
mortality
For CVD mortality
adjusted for age,
previous arterial
disease, cystatin C:
Smoking 3.4 (95% CI
1.3–9.2); aB2GP1 3.4
(95% CI 1.2–9.7); any
aPL medium titer 2.8
(95% CI 1.0–8.2);
warfarin use 3.4 (95%
CI 1–10.4); hsCRP 1.6
(95% CI 1.1–2.3);
soluble VCAM1 5.3
(95% CI 1.3–19.3).
Controlled only for
age: Cystatin C 5.3
(95% CI 2–13),
arterial disease 5.4
(95% CI 2.1–13.6)
Swedish Heart-Lung
Foundation,
Stockholm County
Council and
Karolinska
Institutet (ALF),
Swedish
Rheumatism
Association etc
Touma
et al. [17]
2012 1289 SLE cases,
University of
Toronto
English Prospective
cohort
37 years 90% F 39 (mean
fasting), 35
(mean
nonfasting)
Not speciﬁed Canada CAD (MI, angina) TG (nonfasting and
fasting) 1.15 (95% CI
1.02–1.29); age 1.06
(95% CI 1.04–1.08);
SLEDAI-2K 1.07 (95%
CI 1.03–1.11);
hypertension 1.7
(95% CI 1.07–2.7);
elevated total
cholesterol 1.64 (95%
CI 1.05–2.55); in
stepwise,
Immunosuppressive
meds 1.71 (95% CI
1.09–2.66)
Lupus Ontario Geoff
Carr
Fellowship,Univer-
sity of Toronto
Arthritis Centre of
Excellence
Fellowship, The
Lupus Flare
Foundation,
Arthritis and
Autoimmune
Centre Foundation,
Toronto General-
Toronto Western
Hospital
Foundation and
Smythe
Foundation
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Table A3 (continued )
Author Date of
Publication
Population Language Study Design Duration Gender Age Race Country Outcome
Deﬁnition
Results Funding Source
Yang et al.
[42]
2012 139 SLE cases,
Union
Hospital,
Tongji
Medical
College,
China; 139
controls,
same
hospital
English Retrospective
case control
N/A 84% F 34 (mean) Not speciﬁed China CVD (MI, angina,
PAD, pulmonary
HTN, valvular
disease, cerebral
ischemia)
Elevated serum
creatinine 2.126 (95%
CI 2.004–5.325);
presence of
proteinuria 2.416
(95% CI 1.736–
7.516); anti-Sm
antibody 4.727 (95%
CI 1.136–21.336);
decreased C4 0.008
(95% CI 0.002–
0.337);
hydroxychloroquine
0.067 (95% CI 0.014–
0.735)
National Natural
Science Fund
Program from
National Natural
Science Foundation
of China
Nikpour
et al. [20]
2011 991 SLE cases,
University of
Toronto
English Prospective
cohort
6.4 years 89% F 37 (mean) 70% Caucasian;
11% Black,
11% Asian
Canada CAD events (MI,
angina, sudden
cardiac death)
Time dependent
model: older age
1.13 (95% CI 1.06–
1.20); male sex 1.83
(95% CI 1.01–3.29);
SLEDAI-2K 1.10 (95%
CI 1.06–1.14);
corticosteroid use
2.01 (95% CI 1.19–
3.41); total
cholesterol 2.07
(1.28–3.36). Time
constant model: also
hydroxychloroquine
0.50
Centre for Prognosis
Studies in The
Rheumatic
Diseases, The
Smythe
Foundation, Lupus
Flare Foundation,
Ontario Lupus
Association, and
The Lupus Society
of Alberta
Urowitz
et al. [12]
2010 1289 SLE cases,
SLICC Cohort
English Prospective
cohort
8 years 89% F Not speciﬁed White 49%,
African
American
15%,
Hispanic
16%, Asian
16%
Multina-
tional (11
countries
in North
America,
Asia,
Europe)
Atherosclerotic
vascular event
(CVA, CHF, TIA,
PVD, MI, angina,
PPM insertion)
Older age at diagnosis
1.08 (95% CI 1.05–
1.11); male sex 3.67
(95% CI 1.41–9.52)
Multiple
Haque
et al. [28]
2010 53 SLE cases,
centers from
BILAG and
British
Society of
Rheumatol-
ogy Lupus
Special
Interest
Group; 96
controls,
same centers
English Retrospective
case control
N/A 80% F (cases);
93% F
(controls)
53 (cases
mean)
Not speciﬁed United
Kingdom
CHD (MI or angina) HTN 2.56 (95% CI 1.05–
6.25); family history
3.62 (95% CI 1.15–
11.34); azathioprine
3.18 (95% CI 1.33–
7.59)
Lupus UK
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Gustafsson
et al. [23]
2009 182 SLE cases,
Karolinska
University
Hospital
English Prospective
cohort
8.3 years 90% F 45 (mean) 94% Caucasian,
6% Asian
Sweden CVE (MI, angina,
CVA, TIA, PVD, or
death due to
CVD)
Age 2.39 (95% CI 1.71–
3.32);
thrombocytopenia
0.35 (95% CI 0.08–
0.77); positive aPL
4.23 (95% CI 1.56–
14.83); von
Willebrand factor
1.97 (95% CI 1.16–
3.33)
Swedish Heart-Lung
Foundation,
Swedish
Rheumatism
Association, Centre
of Gender related
Medicine at
Karolinska
Institute etc.
Burgos
et al. [14]
2009 637 SLE cases,
LUMINA
Cohort
English Prospective
cohort
4.4 years 90% F 36.5 (mean) Texan-Hispanic
18%, Puerto
Rican-
Hispanic
16%, African-
American
37% and
Caucasian
28%
USA Peripheral vascular
damage by SDI
Age 1.05 (95% CI 1.01–
1.08); damage Index
1.3 (95% CI 1.09–
1.56); azathioprine
3.2 (95% CI 1.34–
7.64); warfarin 6.16
(95% CI 2.43–15.59);
statin 0.2 (95% CI
0.05–0.8)
National Institute of
Arthritis and
Musculoskeletal
and Skin Diseases,
NCRR/HIH, RCRII,
STELLAR
Goldberg
et al. [21]
2009 241 SLE cases,
University of
Toronto SLE
Clinic
English Prospective
cohort
7.2 years 100% F 44.2 (mean) SLE: 77%
White, 10%
Black, 6%
Chinese, 7%
Other;
Controls: 89%
White, 3%
Black, 5%
Chinese, 3%
Other
Canada CAD (MI and
angina)
Age 1.08 (95% CI 1.04–
1.12); total TG 7.96
(95% CI 2.65–23.97);
SLE 4.23 (95% CI
1.49–11.97)
Heart and Stroke
Foundation, The
Ontario Lupus
Association, and
the Lupus Flare
Foundation
Bertoli
et al. [22]
2009 1333 SLE cases,
PROFILE
Cohort
English Prospective
cohort
6.4 years 90% F 35.7 (mean) 10.4% Texan
Hispanics;
7.7% Puerto
Rican
Hispanics;
35.4%
African-
Americans;
46.5%
Caucasians
USA Time to CVE (MI,
angina, vascular
procedure for MI,
CVA,
claudication,
gangrene or
tissue loss)
Current smoking 2.2
(95% CI 1.4–3.46);
CRP2nC alleles 1.91
(95% CI 1.04–3.49);
age at cohort
enrollment 1.04 (95%
CI 1.03–1.06);
arthritis 0.32 (95% CI
0.18–0.58);
psychosis 2.21 (95%
CI 1.18–4.44);
seizures 1.85 (95% CI
1.05–3.24); SDI 1.1
(95% CI 1.0–1.22);
anemia 1.83 (95% CI
1.02–3.31)
National Institute of
Arthritis and
Musculoskeletal
and Skin Diseases;
National Center for
Research
Resources/National
Institutes of Health
RCMI Clinical
Research
Infrastructure
Initiative; Bristol
Myers Squibb
educational grant;
General Clinical
Research Centers
Pons-Estel
et al. [30]
2009 637 SLE cases,
LUMINA
Cohort
English Prospective
cohort
6.6 years 90% F 36.8 (mean) Texan-Hispanic
18%, Puerto
Rican-
Hispanic
16%, African-
American
37% and
Caucasian
28%
USA CVE (angina, CABG,
MI, CHF)
Age 1.06 (95% CI 1.03–
1.09); male sex 3.57
(95% CI 1.35–9.09);
highest tertile CRP
2.63 (95% CI 1.17–
5.91); disease
damage (SDI
excluding CV
domain) 1.28 (95% CI
1.09–1.5); # years
education 0.84 (95%
CI 0.74–0.94)
National Institute of
Arthritis and
Musculoskeletal
and Skin Diseases,
General Clinical
Research Centers,
National Center for
Research Resources
(NCRR/NIH) RCMI
Clinical Research
Infrastructure
Initiative (RCRII),
STELLAR
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Table A3 (continued )
Author Date of
Publication
Population Language Study Design Duration Gender Age Race Country Outcome
Deﬁnition
Results Funding Source
Mikdashi
et al. [19]
2007 232 SLE cases,
Maryland
Lupus Clinic
English Prospective
cohort
8 years 90% F Not speciﬁed 66% Black USA Ischemic stroke,
severe ischemic
stroke (NIHSS Z
6)
Any stroke: HTN
2.31(95% CI 1.15–
4.65); cholesterol
1.09 (95% CI 1.02–
1.16); baseline
SLEDAI 2.09 (95% CI
1–4.6). Severe
stroke: HTN 3.17
(95% CI 1.38–7.32);
cholesterol 1.12 (95%
CI 1.04–1.21);
baseline SLEDAI 2.56
(95% CI 1.0–6.4)
Ofﬁce of Research
and Development,
Medical Research
Service, the
Baltimore Research
Enhancement
Award Program in
Stroke and the
Baltimore
Geriatrics
Research,
Education, and
Clinical Center of
the Department of
Veterans Affairs;
NINDS; NIH
ORWH; NIA
Urowitz
et al. [26]
2007 1087 (total),
561
(inception)
SLE cases,
University of
Toronto
English Prospective
cohort
8.4 years 96% F 31.9 (mean) 79% Caucasian,
8% Blacks, 7%
Chinese, and
6% Other
Canada Atherosclerotic
vascular events
(MI, angina, PVD,
TIA, stroke,
sudden death)
Inception Cohort:
Neuropsychiatric
disease 3.7 (95% CI
1.33–10.32);
smoking 3.28 (95% CI
1.14–9.43). Total
cohort:
Neuropsychiatric
disease 2.19 (95% CI
1.05–4.59); vasculitis
2.26 (95% CI 1.22–
4.17); # of CAD-risk
factors 1.76 (95% CI
1.26–2.47)
The Arthritis Society,
Canadian Institutes
for Health
Research, and the
Krembil
Foundation
Bessant
et al. [29]
2006 29 SLE cases w/
o CVD,
Birmingham
Lupus
Cohort; 58
SLE cases w/o
CVD, same
cohort
English Retrospective
Case Control
N/A 83%F 48 (mean) 72% White, 17%
Asian, 10%
African
Caribbean
United
Kingdom
CVD (MI, angina,
cerebral
infarction, PVD)
Age matched controls:
Treatment for HTN
(no OR reported).
Duration matched
controls: treatment
for HTN (no OR
reported)
Lupus UK, Arthritis
Research
Campaign, and the
Wellcome Trust
Clinical Research
Facility
Ruiz-
Irastorza
et al. [36]
2006 232 SLE cases,
IM
Department
Hospital de
Cruces,
University of
the Basque
Country,
Spain
English Prospective
cohort
10.6 years 88% F 36.2 (mean) 99% White Spain Thrombosis (DVT,
PE, MI, PVD,
stroke, TIA),
death from any
cause
Antimalarials 0.28 (95%
CI 0.08–0.90); aPL Ab
positive 3.16 (95% CI
1.45–6.88); previous
thrombosis 3.85 (95%
CI 1.50–9.91)
Not speciﬁed
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Toloza
et al. [25]
2004 546 SLE cases,
LUMINA
Cohort
English Prospective
cohort
73.8
months
(median)
90% F 36.5 (mean) 35.1% Hispanic,
36.6% African
American,
28.4%
Caucasian
USA CVE (MI, angina,
vascular
procedure, CABG,
CVA, TIA, PVD)
Age 1.075 (95% CI
1.037–1.114);
current smoking
3.731 (95% CI 1.391–
10.000); follow-up
time 1.452 (95% CI
1.223–1.725); CRP
3.356 (95% CI 1.264–
8.929); aPL Ab 4.717
(95% CI 1.675–
13.158);
azathioprine 1.452
(95% CI 1.215–
10.378)
NIH etc
Manzi et al.
[7]
1997 498 SLE cases,
UPMC
English Retrospective
cohort
14 years 100% F 15–74, age
stratiﬁed
SLE: 76%
Caucasian,
22% African
American, 2%
American
Indian, Asian
American,
and Eastern
Indian:
Control:
100%
Caucausian
USA CVE (MI/angina) Disease duration 0.83
(95% CI 0.74–0.92);
hypercholesterole-
mia 3.35 (95% CI
1.34–8.36); older age
at diagnosis 1.21
(95% CI 1.09–1.35)
Commonwealth of
Pennsylvania
(Department of
Health); Lupus
Foundation of
America, Western
Pennsylvania
Chapter; and
Pennsylvania
Lupus Foundation,
Inc.
Petri et al.
[34]
1996 337 SLE cases,
Johns
Hopkins
Lupus Cohort
English Prospective
cohort
4.8 years 93% F 34.9 (mean) 54% African
American,
45% White
USA Stroke, arterial
thrombotic
events
(thromboembolic
stroke, MI,
gangrene of
ﬁngers, other),
venous
thrombotic
events (DVT,
Budd Chiari)
Stroke: homocysteine
2.44 (95% CI 1.04–
5.75)
National Institutes of
Health, American
Heart Association;
the Arthritis
Foundation;
General Clinical
Research Center,
USDA
Petri et al.
[18]
1992 229 SLE cases,
Johns
Hopkins
Lupus Cohort
English Prospective
cohort
3 years 93% F 34.9 (mean) 54% African
American,
45% White
USA CAD (MI, angina,
sudden death)
HTN, hyperlipidemia,
obesity, age at SLE
diagnosis, duration
of glucocorticoid use
NIH
Abbreviations: CVE ¼ cardiovascular event, MI ¼ myocardial infarction, CI ¼ conﬁdence interval, CVD ¼ cardiovascular disease, MI ¼ myocardial infarction, PAD ¼ peripheral vascular disease, HTN ¼ hypertension, CAD ¼
coronary artery disease, CVA ¼ cerebrovascular disease, CHF ¼ congestive heart failure, TIA ¼ transient ischemic attack, PVD ¼ peripheral vascular disease, PPM ¼ permanent pacemaker, CHD ¼ coronary heart disease, CABG
¼ coronary artery bypass grafting, DVT ¼ deep vein thrombosis, PE ¼ pulmonary embolism.
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Table A4
Risk of Bias for Studies Investigating Risk Factors for CVD Among SLE Patients.
Study Population Study Design Selection Bias Measurement Bias Control for
Confounders
Comments
Representa-
tive pop
Participation
Rate
Recall Bias Outcome
Deﬁnition
Outcome
Measure-
ment Method
Bengtsson et al. [11] 277 SLE cases, Northern Sweden Prospective cohort L L N/A L L L Database for inpatient admissions and
death; would miss events not
requiring hospitalization
Gustafsson et al. [24] 208 SLE cases, Karolinska University
Hospital
Prospective cohort L UTD N/A L L L Unclear how population was chosen
from the hospital
Touma et al. [17] 1289 SLE cases, University of Toronto Prospective cohort L L UTD UTD UTD L Unclear how outcomes and
measurement are deﬁned
Yang et al. [42] 139 SLE cases, Union Hospital, Tongji
Medical College, China; 139
controls, same hospital
Retrospective case
control
L UTD H L L H Relied on patient reporting of
outcomes; only patient reported
events were conﬁrmed by medical
record review
Nikpour et al. [20] 991 SLE cases, University of Toronto Prospective cohort L L L L L L Outcomes validated by a cardiologist
Urowitz et al. [12] 1289 SLE cases, SLICC Cohort Prospective cohort L L N/A L H L Relied on physician judgment of SLE
vs. atherosclerotic event; did use
imaging in cases to conﬁrm
Haque et al. [28] 53 SLE cases, centers from BILAG and
British Society of Rheumatology
Lupus Special Interest Group; 96
controls, same centers
Retrospective case
control
H L N/A L H H Missing up to 20% of information
regarding hyperlipidemia, FH,
ethnicity
Gustafsson et al. [23] 182 SLE cases, Karolinska University
Hospital
Prospective cohort L L L L L L
Burgos et al. [14] 637 SLE cases, LUMINA Cohort Prospective cohort L L N/A L L L
Goldberg et al. [21] 241 SLE cases, University of Toronto
SLE Clinic
Prospective cohort L L H L L L Controls only followed through
telephone interviews; potential for
high recall bias for controls
Bertoli et al. [22] 1333 SLE cases, PROFILE Cohort Prospective cohort L L UTD L UTD L Unclear how outcomes are measured
Pons-Estel et al. [30] 637 SLE cases, LUMINA Cohort Prospective cohort L L N/A L L L
Mikdashi et al. [19] 232 SLE cases, Maryland Lupus Clinic Prospective cohort L L N/A L L L Conducted at potential referral center
for neuropsychiatric SLE
Urowitz et al. [26] 1087 (total), 561 (inception) SLE
cases, University of Toronto
Prospective cohort L L N/A L L L
Bessant et al. [29] 29 SLE cases w/ CVD, Birmingham
Lupus Cohort; 58 SLE cases w/o
CVD, same cohort
Retrospective Case
Control
L L L L L L
Ruiz-Irastorza et al. [36] 232 SLE cases, IM Department
Hospital de Cruces, University of
the Basque Country, Spain
Prospective cohort H L N/A L L H 8% lost to follow-up; included PE and
DVT as thrombosis end points
Toloza et al. [25] 546 SLE cases, LUMINA Cohort Prospective cohort L L N/A L L L
Manzi et al. [7] 498 SLE cases, UPMC Retrospective cohort L L H L L H Relied on self-reporting of events,
then conﬁrmed with medical record
review; only controlled for age in
multivariate analysis
Petri et al. [34] 337 SLE cases, Johns Hopkins Lupus
Cohort
Prospective cohort L L N/A L L L
Petri et al. [18] 229 SLE cases, Johns Hopkins Lupus
Cohort
Prospective cohort L L L L L L
Abbreviations: H ¼ high risk that methodology may have resulted in bias in the speciﬁed domain, L ¼ low risk that methodology may have resulted in bias in the speciﬁed domain, N/A ¼ not applicable, UTD ¼ unable to
determine risk of bias from methodology.
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